Oddo BHF - BB Biotech AG 3rd Line (BIOEE) BB Biotech AG : Q2 18 preview: Mixed portfolio performance; FX tailwind from stronger USD

Report

Oddo BHF

BB Biotech AG : Q2 18 preview: Mixed portfolio performance; FX tailwind from stronger USD

>Flat performance in Q2 despite FX tailwind - In Q2 2018, BB Biotechâ€™s share price in EUR increased just slightly â€“ by 2% â€“ and thus underperform its sector benchmark, the Nasdaq Biotech (up 7% in EUR). Despite a currency tailwind from the stronger USD, BB Biotechâ€™s Q2 2018 overall portfolio performance was unimpressive due to mixed performances among individual portfolio positions (see below). In Q2 2018 BB Biotechâ€™s portfolio NAV decreased 1% yoy. The NAV premium st...

04/07/2018 4 EN

Underlying

BB Biotech AG 3rd Line

See profile

CH0027659793 Six Swiss Exchange Switzerland

Provider

Oddo BHF

Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.

See profile

Other Reports on these Companies

Oddo BHF

ODDO BHF GERMAN MORNING NEWS â€“ DETAILED COMMENTS 07.05.2018

...

July 5, 2018 July 5, 2018 9 EN

Wendel : Q1 NAV: € 178.1/share, +11% YTD, driven by BVI, and a little by unlisted holdings

>Q1 NAV: € 178.1m/share, good growth level - Wendel reported Q1 2024 NAV of € 178.1, up vs end-2023 (€ 160.2). In detail, the valuation of listed holdings rose by 20% (+€ 0.7bn, including +€ 0.8bn for BVI and -€ 0.1bn for IHS). The valuation of unlisted companies is up very slightly by 2% (with Stahl and CPI well oriented, unlike Acams and Scalian). The LTV remains very controlled, at -5.1% pro forma for the sale of the BVI block (€ 1.1bn) and the dividend paid b...

1h / 2m 1h / 2m 1 EN

Martin Marandon-Carlhian ... (+2)

Martin Marandon-Carlhian
Stephane Houri

ams OSRAM : Q1 2024 results in line, Q2 guidance below expectations, improving FCF trend

>Q1 2024 results globally in line with expectations but above on FCF - This morning, ams OSRAM reported its Q1 2024 results which were globally in line with expectations. Revenues were € 847m, in line with the Visible Alpha consensus at € 845m. They were down 7% q-o-q and down 9% y-o-y but up 5% y-o-y on a like-for-like basis. The main drivers for this year-on-year increase are the automotive (+13% y-o-y) and consumer (+15% y-o-y) semiconductor businesses, whilst indu...

1h / 4m 1h / 4m 1 EN

Martin Marandon-Carlhian ... (+2)

Martin Marandon-Carlhian
Stephane Houri

ams OSRAM : Q1 2024 results in line, Q2 guidance below expectations, improving FCF trend

1h / 6m 1h / 6m 1 FR

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

BB Biotech AG : Q2 18 preview: Mixed portfolio performance; FX tailwind from stronger USD

ODDO BHF GERMAN MORNING NEWS â€“ DETAILED COMMENTS 07.05.2018

Wendel : Q1 NAV: € 178.1/share, +11% YTD, driven by BVI, and a little by unlisted holdings

ams OSRAM : Q1 2024 results in line, Q2 guidance below expectations, improving FCF trend

ams OSRAM : Q1 2024 results in line, Q2 guidance below expectations, improving FCF trend

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe